The assessment of the suitability of novel targets to intervention by different modalities, e.g. small molecules or antibodies, is increasingly seen as important in helping to select the most progressable targets at the outset of a drug discovery project.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: